In the News
Partner of Choice: Aitia and Servier Revolutionize the Landscape of Pancreatic Cancer Treatment
Spotlight on our collaboration with Servier to discover and simulate drugs in Pancreatic Cancer.
Charles River and Aitia Join Forces to Harness AI and Gemini Digital Twins in Advancing Neurodegenerative and Oncology Research
Aitia reached a deal that lets it access Charles River Labs’ AI drug solution platform to speed the development of several therapy programs in neurodegenerative and oncology.
Hear What Colin Hill had to say to Sidley on AI Use in Drug Discovery
Stephen Abreu, Sidley partner, talks to our Colin Hill about how the use of AI is revolutionizing the biotech space…
Webinar | From the beta-amyloid hypothesis to AI-driven discoveries of novel biomarkers and breakthrough drugs in Alzheimer’s Disease
Time to dive into the forefront of Alzheimer’s disease research! Join us for an exclusive on-demand webinar featuring Dr. Rudolf Tanzi, renowned expert and co-discoverer of all three early-onset familial Alzheimer’s disease genes, John Dwyer, President of the Global Alzheimer’s Platform Foundation (GAP), and our CEO, Colin Hill.
Exploring the Frontiers of AI-driven Drug Discovery: A Conversation with Aitia on The Long Run Podcast
Colin Hill joined Luke Timmerman on “The Long Run” podcast, to explore Aitia’s journey and its impact on the realm of drug discovery…
Servier and Aitia Mobilize AI and Digital Twins to Treat Pancreatic Cancer
The French pharmaceutical group Servier and Aitia announced on May 17th a multi-year partnership agreement for the discovery and simulation of drugs in pancreatic cancer. It is based on the combination of Servier’s expertise in preclinical trials with Aitia’s technology, which is based on artificial intelligence and Gemini Digital Twins…
Colin Hill Weighs in on the Future of Drug Discovery on the Patients Rising Podcast
In this week’s episode of the Patients Rising podcast, Colin passionately shared his beliefs and vision for the future of medical research, highlighting the transformative potential of AI-powered clinical trials and the revolutionary power of Digital Twins…
Open to Debate: Is the FDA’s Caution Hazardous to your Health?
As the FDA tries to move safe and effective drugs as quickly as possible to patients who need them, it also needs to maintain the diligence and rigor necessary to prevent harms. Two experts look at the pace of FDA approvals and argue whether the agency is getting it right…
World Congress: AI and Digital Twins to Drive the Next Generation Drug Discovery and Development
Watch Colin Hill’s talk at Charles River’s sixth Annual World Congress on May 11, 2023, in Cambridge, MA. Colin’s session focused on “Al and Digital Twins to Drive the Next Generation of Drug Discovery and Development”. The presentation was followed by a fireside chat with Julie Frearson, Chief Scientific Officer at Charles River Laboratories…
Servier Doubles Up on Digital Twin Alliance with Aitia
French pharma group Servier has formed a second partnership with Aitia focusing on the use of artificial intelligence and digital twins to help discover and develop new therapies for cancer.